Bristol Myers Squibb 2025 Revenue Miss
This is a news story, published by Yahoo Finance, that relates primarily to Revlimid news.
Revlimid news
For more Revlimid news, you can click here:
more Revlimid newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Bristol Myers. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cancer drug Revlimid news, sharp revenue loss news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
total cost cutsReuters
•Health
Health
Bristol Myers forecasts 2025 revenue below estimates after strong quarter

80% Informative
Shares of the drugmaker fell nearly 4% to $ 57.33 before the bell.
The company forecast 2025 revenue of around $45.5 billion , down from $48.3 billion in 2024 .
Bristol has already been contending with sharp revenue loss from its cancer drug Revlimid , which brought in nearly $13 billion in 2021 .
VR Score
92
Informative language
98
Neutral language
71
Article tone
formal
Language
English
Language complexity
36
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links